Literature DB >> 34044079

A systematic review on Zhilong Huoxue Tongyu capsule in treating cardiovascular and cerebrovascular diseases: Pharmacological actions, molecular mechanisms and clinical outcomes.

Pan Liang1, Linshen Mao1, Yue Ma1, Wei Ren2, Sijin Yang3.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Cardiovascular and cerebrovascular diseases have become a severe threat for human health worldwide, however, optimal therapeutic options are still developed. Zhilong Huoxue Tongyu capsule (ZL capsule) is mainly composed of Astragalus membranaceus, Leech, Earthworm, Cinnamomum cassia and Sargentodoxa cuneata, having functions of replenishing qi and activating blood, dispelling wind and reducing phlegm. It is an expanded application on the basis of traditional uses of above TCMs, acquiring a satisfactory curative effect on cardiovascular and cerebrovascular diseases over twenty years. AIM OF THE STUDY: To comprehensively summarize the main components of ZL capsule, understand the mechanisms of ZL capsule, and conclude clinical regimens of ZL capsule for cardiovascular and cerebrovascular diseases.
MATERIALS AND METHODS: We selected network pharmacology technology to analyze main active compounds and predict underlying mechanism of ZL capsule against atherosclerosis. Molecular docking was performed to simulate the interaction pattern between the active components of ZL capsule and putative targets. Further, PubMed, Web of Science, China National Knowledge Infrastructure and Google Scholar were used to search literatures, with the key words of "Zhilong Huoxue Tongyu capsule", "cardiovascular and cerebrovascular diseases", "atherosclerosis", "clinical study" and their combinations, mainly from 2000 to 2020.
RESULTS: Both network pharmacology analysis, molecular docking and animal experiments studies confirmed that mechanisms of ZL capsule plays the role of anti-inflammatory, anti-apoptosis and promoting angiogenesis in treating cardiovascular and cerebrovascular diseases by multi-components acting on multi-targets via multi-pathways. Over 1000 clinical cases were benefited from the treatment of ZL capsule, suggesting a holistic concept of "the same therapy for different myocardial and cerebral diseases".
CONCLUSIONS: For the first time, this systematic review may supply meaningful information for further studies to explore material basis and pharmacodynamics of ZL capsule and also provide a basis for sharing the "Chinese patent medicine" for cardiovascular and cerebrovascular diseases.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Cardiovascular and cerebrovascular diseases; Mechanism; Network pharmacology; Zhilong huoxue tongyu capsule

Year:  2021        PMID: 34044079     DOI: 10.1016/j.jep.2021.114234

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  5 in total

1.  Zhilong Huoxue Tongyu Capsule Alleviated the Pyroptosis of Vascular Endothelial Cells Induced by ox-LDL through miR-30b-5p/NLRP3.

Authors:  Mengnan Liu; Gang Luo; Tianzhu Liu; Tingfu Yang; Raoqiong Wang; Wei Ren; Ping Liu; Xiaoling Lai; Hua Zhou; Sijin Yang
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-27       Impact factor: 2.629

2.  Zhilong Huoxue Tongyu Capsules Ameliorate Early Brain Inflammatory Injury Induced by Intracerebral Hemorrhage via Inhibition of Canonical NFкβ Signalling Pathway.

Authors:  Maryam Mazhar; Guoqiang Yang; Linshen Mao; Pan Liang; Ruizhi Tan; Li Wang; Houping Xu; Luyin Yang; Wei Ren; Sijin Yang
Journal:  Front Pharmacol       Date:  2022-03-31       Impact factor: 5.810

3.  Study on the Mechanism and Oxidative Stress of Compound Danshen on the Degradation of Cx43 and Improvement of Myocardial Apoptosis in ICM Rats.

Authors:  XingHua Chen; JiZhuo Zhang; Lu Han
Journal:  J Healthc Eng       Date:  2022-04-12       Impact factor: 3.822

4.  Gene Network Mechanism of Zhilong Huoxue Tongyu Capsule in Treating Cerebral Ischemia-Reperfusion.

Authors:  Na Li; Jie Sun; Ji-Lin Chen; Xue Bai; Ting-Hua Wang
Journal:  Front Pharmacol       Date:  2022-07-07       Impact factor: 5.988

5.  Exploring the Ferroptosis Mechanism of Zhilong Huoxue Tongyu Capsule for the Treatment of Intracerebral Hemorrhage Based on Network Pharmacology and In Vivo Validation.

Authors:  Lixia Wang; Wei Ren; Li Wang; Linshen Mao; Maryam Mazhar; Chen Zhou; Houping Xu; Sijin Yang
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-25       Impact factor: 2.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.